Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 6Unknown 1Terminated 1Recruiting 1Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1Gastrointestinal 1Breast 1

Conditions

Melanoma 50Carcinoma, Non-Small-Cell Lung 12Neoplasms 11Neoplasm Metastasis 10Carcinoma, Renal Cell 7Skin Neoplasms 5Prostatic Neoplasms 4Ovarian Neoplasms 4Lung Neoplasms 4Glioblastoma 4Diabetes Mellitus, Insulin-Dependent, 12 4Carcinoma, Hepatocellular 4Brain Neoplasms 4Advanced Cancer 4Uveal Melanoma 3Triple Negative Breast Neoplasms 3Squamous Cell Carcinoma of Head and Neck 3Small Cell Lung Carcinoma 3Recurrence 3Precursor Cell Lymphoblastic Leukemia-Lymphoma 3Pancreatic Neoplasms 3Multiple Myeloma 3Lymphoma, Non-Hodgkin 3Lymphoma 3Leukemia, Lymphocytic, Chronic, B-Cell 3Breast Neoplasms 3Waldenstrom Macroglobulinemia 2Sarcoma 2Myeloproliferative Disorders 2Lymphoma, Mantle-Cell 2

Interventions

Capecitabine 27pembrolizumab 19Oxaliplatin 19Fluorouracil 17Cisplatin 17Trastuzumab 14Docetaxel 14Leucovorin 11Paclitaxel 8Irinotecan 8S 1 (combination) 7Epirubicin 6Cyclophosphamide 5tegafur-gimeracil-oteracil 4aldesleukin 4Hyperthermic Intraperitoneal Chemotherapy 4titanium silicide 3spartalizumab 3fludarabine phosphate 3fludarabine 3Surveys and Questionnaires 3Surgical Procedures, Operative 3Ramucirumab 3Nivolumab 3Indocyanine Green 3Gemcitabine 3Carboplatin 3Albumin-Bound Paclitaxel 3Ado-Trastuzumab Emtansine 3vistusertib 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Stomach Neoplasms × Ipilimumab × Clear all
NCT03342417 2021-11-09

Combination of Nivolumab and Ipilimumab in Breast, Ovarian and Gastric Cancer Patients

ExcellaBio LLC

Phase 2 Terminated
5 enrolled
BreastGastrointestinalGynecologic

Breast Neoplasms, Ovarian Neoplasms, Stomach Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡